Odyssey Therapeutics, Inc. (ODTX)
| Market Cap | 936.33M |
| Revenue (ttm) | 99,000 -96.7% |
| Net Income | -160.03M |
| EPS | -14.05 |
| Shares Out | 47.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 166,394 |
| Open | 19.77 |
| Previous Close | 19.83 |
| Day's Range | 19.12 - 20.20 |
| 52-Week Range | 15.10 - 29.05 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 35.33 (+80.81%) |
| Est. Earnings | Nov 12, 2026 |
About ODTX
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis... [Read more]
Financial Performance
In 2025, Odyssey Therapeutics's revenue was $2.98 million, a decrease of -33.45% compared to the previous year's $4.47 million. Losses were -$148.65 million, 14.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ODTX stock is "Strong Buy." The 12-month stock price target is $35.33, which is an increase of 80.81% from the latest price.
News
Odyssey Therapeutics Transcript: Investor update
OD-001 showed 27% clinical remission at 20 mg BID, with biomarker and tissue findings supporting the dose and RIPK2 mechanism. Phase II-B monotherapy and vedolizumab combination trials were planned, with induction readouts targeted for H2 2027.
Odyssey Therapeutics Press release: Investor update
Odyssey Therapeutics issued a press release on October 20, 2026, disclosing material business information to investors.
Odyssey Therapeutics Slides: Investor update
Odyssey Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2026.
Odyssey Therapeutics reports OD-001 trial meets primary endpoint
Odyssey Therapeutics (ODTX) announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with mod...
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in IBD
Odyssey Therapeutics initiated with a Buy at UBS
UBS initiated coverage of Odyssey Therapeutics (ODTX) with a Buy rating and $27 price target The firm views the company’s OD-001, a novel oral RIPK2 inhibitor, as a promising new…
Odyssey Therapeutics initiated with an Outperform at Raymond James
Raymond James initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $42 price target Odyssey’s lead asset OD-001 is in Phase 2 development for inflammatory bowel diseases, in...
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Od...
Odyssey Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
The forum highlighted a robust pipeline targeting autoimmune and inflammatory diseases, with lead RIPK2 inhibitor showing promising phase IIA results in ulcerative colitis and plans for combination and monotherapy trials. Additional programs in SLC15A4 and TNFR2 agonism are advancing, supported by strong financials into 2028.
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care ...
Odyssey Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted an innovation-driven pipeline targeting upstream immune pathways for durable remissions in inflammatory and autoimmune diseases. OD-001 showed promising phase IIa results in IBD, with rapid efficacy even in refractory patients. Multiple clinical readouts are expected by 2027, with a focus on rapid development and commercialization.
H.C. Wainwright has increased confidence in Odyssey after Beeline data
H.C. Wainwright says Beeline Medicines’ Phase 2 success of afimetoran in systemic lupus erythematosus increases the firm’s confidence in Odyssey Therapeutics (ODTX)’ OD-002. The Beeline trial success ...
Odyssey Therapeutics Slides: Corporate presentation
Odyssey Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Odyssey Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar initiated coverage of Odyssey Therapeutics (ODTX) with a Buy rating and $44 price target The company is developing precision small molecules and protein therapeuti...
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care f...
Evotec enters R&D collaboration with Odyssey Therapeutics
Evotec (EVO) announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics (ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreem...
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Ody...
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b...
Odyssey Therapeutics Earnings release: Q2 2026
Odyssey Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Odyssey Therapeutics Quarterly report: Q2 2026
Odyssey Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Odyssey Therapeutics Slides: Corporate presentation
Odyssey Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on han...
Odyssey Therapeutics Quarterly report: Q1 2026
Odyssey Therapeutics has published its Q1 2026 quarterly earnings report on June 17, 2026.
Odyssey Therapeutics Earnings release: Q1 2026
Odyssey Therapeutics released its Q1 2026 earnings on June 17, 2026, summarizing the period's financial results.
Wedbush bullish on Odyssey Therapeutics, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $30 price target Odyssey’s lead candidate OD-001 is an oral RIPK2 scaffolding inhibitor ...